Master Rollover Protocol for Continued Safety Assessment of Study Drug

NCT02632994 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: LY2503029
DRUG: LY3023414
DRUG: LY3838915
DRUG: LY3847429

Sponsor

Eli Lilly and Company